Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior
about
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseA high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn diseaseClinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patientsThe role of the innate and adaptive immune system in pediatric inflammatory bowel disease.Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.Factors affecting outcomes in Crohn's disease over 15 years.Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic PerspectiveImpact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases.Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocyte-macrophage colony stimulating factor autoantibodiesAdvances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.Current and future role of serogenomics in ulcerative colitis.Have genomic discoveries in inflammatory bowel disease translated into clinical progress?How does knowledge from translational research impact our clinical care of pediatric inflammatory bowel disease patients?Endoscopic management of inflammatory bowel disease strictures.Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression?Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum.Personalizing therapy for inflammatory bowel diseases.Towards personalized care in IBD.Future directions in inflammatory bowel disease management.Systems biology approaches for inflammatory bowel disease: emphasis on gut microbial metabolism.The use of prognostic factors in inflammatory bowel diseases.Predicting outcomes in acute severe ulcerative colitis.Overcoming difficulty in diagnosis and differential diagnosis of Crohn's disease: the potential role of serological and genetic tests.A Personalized Approach to Managing Inflammatory Bowel Disease.B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.Genetic susceptibility and genotype-phenotype association in 588 Danish children with inflammatory bowel disease.Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.Serologic antibodies in relation to outcome in postoperative Crohn's disease.Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort.Serum antibodies associated with complex inflammatory bowel disease.Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn's disease.
P2860
Q26745721-83458B79-F0DC-4F1B-9BA8-97240CE9BCB2Q30405495-A8124F20-545D-4D53-96D8-FE1A6544ECF9Q33715448-745DDD3E-9B0D-4F42-B3F0-B5FC59F696CAQ33830707-23429ADA-F37D-466C-8C92-5C54D336FB26Q35748693-ABC1AC9D-1ACD-49E3-A682-2E0A9C380A90Q36073254-9DE507C1-4B80-4AA2-AD7B-32A3E9DD3C2FQ36604130-A1A606DB-EEDE-4438-B300-2EE0B2E16345Q37353271-49DFF83E-7786-4D46-8191-592147791EDAQ37633768-38D849DF-7E9F-43C4-B3A0-49AE36E3B867Q37703514-FC3701EE-C376-4BD9-A215-2097504E7ADAQ37980742-3A5B46A9-70E8-4CF4-893B-D596353545D0Q37981121-6B56792C-3DB9-4CD3-9B51-792F67F8E6BDQ37994130-40B92731-1E35-4AC6-B363-39A41771C112Q38063200-6CE0A9AF-7EE0-4AEC-9D82-E45583DC393DQ38072225-D4EC8AE7-998C-420D-B3BE-03E8A88B594EQ38079831-ED46E1E1-E0BF-47AF-8D26-9C182BA721FEQ38132279-F01301B2-CA5E-44FB-A16E-353C991DBA0CQ38171924-7DB332D8-BCA6-46A1-AB2B-C6311513356DQ38205305-A151438D-DFFE-482C-95AC-0BEA8B371E5AQ38230162-2E72A707-394C-4A7D-A6DD-3504B862946AQ38254878-59AEE91D-1BE3-48A5-B82A-75F48F98E9CBQ38286166-6EC7BEB6-7F0A-4C86-B7A4-B11420F1BA8BQ38570962-DAB03C14-00DB-43AA-BF81-7E560681F329Q38833619-0757C22A-7A97-4EB2-9FD9-A9EDC2C3FF30Q38961202-FBAF1D45-ABC3-4623-B361-28D495D5C6B1Q38986222-5E6BA455-F1F2-4557-825F-A8A9931E967EQ39278831-87EC5792-2CC1-4654-8FC1-D2C76D9D2630Q40141872-DBFE6E80-EC29-4880-8600-D2E0FA5DA459Q40409129-848E6135-A623-41D8-8199-E867C619ABDCQ45331934-701BE8AB-C964-43BC-95D1-42A67635E471Q50965440-F9686685-6FA0-43D9-8DE6-A21975090B45Q54119470-BBD1A875-CC94-462D-982C-3487B6D91A5B
P2860
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Combination of genetic and qua ...... cated Crohn's disease behavior
@ast
Combination of genetic and qua ...... cated Crohn's disease behavior
@en
Combination of genetic and qua ...... cated Crohn's disease behavior
@nl
type
label
Combination of genetic and qua ...... cated Crohn's disease behavior
@ast
Combination of genetic and qua ...... cated Crohn's disease behavior
@en
Combination of genetic and qua ...... cated Crohn's disease behavior
@nl
prefLabel
Combination of genetic and qua ...... cated Crohn's disease behavior
@ast
Combination of genetic and qua ...... cated Crohn's disease behavior
@en
Combination of genetic and qua ...... cated Crohn's disease behavior
@nl
P2093
P2860
P356
P1476
Combination of genetic and qua ...... cated Crohn's disease behavior
@en
P2093
Carol J Landers
Derren M Barken
Emil Chuang
Fred Princen
Gary R Lichtenstein
Joanne M Stempak
Jordan Stachelski
Mark S Silverberg
Marla C Dubinsky
Michelle Brown
P2860
P304
P356
10.1002/IBD.21661
P577
2011-03-09T00:00:00Z